International Journal of Women''s Dermatology最新文献

{"title":"Allergic contact dermatitis of the scalp: a review of an underdiagnosed entity.","authors":"Jonathan C Hwang, Colleen J Beatty, Kuzma Khobzei, Viktoryia Kazlouskaya","doi":"10.1097/JW9.0000000000000167","DOIUrl":"10.1097/JW9.0000000000000167","url":null,"abstract":"<p><strong>Background: </strong>It is hypothesized that scalp allergic contact dermatitis (ACD) in women is commonly mistaken for other disorders due to overlapping symptoms and unique clinical presentations.</p><p><strong>Objective: </strong>This study reviews the potential underdiagnosis and misdiagnosis of scalp ACD and explores ways to improve diagnostic accuracy.</p><p><strong>Methods: </strong>This study conducted an extensive literature review to identify diagnostic challenges, common misdiagnoses, and diagnostic approaches for scalp ACD, focusing on standard versus targeted patch testing techniques.</p><p><strong>Results: </strong>Scalp ACD, often misdiagnosed as seborrheic dermatitis due to similar symptoms, has atypical presentations such as hair thinning, hair loss, and erythematous lesions affecting neighboring regions. Trichoscopy can help distinguish scalp ACD, identifying its patchy distribution of thin white scales, in contrast to the yellow scaling of seborrheic dermatitis. Standardized patch testing further contributes to diagnostic errors, with a study reporting 83% of patients who tested negative with standardized patch tests were positive when using their personal products. Individualized patch testing is more effective in identifying causative allergens and accurately diagnosing scalp ACD.</p><p><strong>Limitations: </strong>It is a retrospective review.</p><p><strong>Conclusion: </strong>Several factors contribute to scalp ACD's misdiagnosis for conditions such as seborrheic dermatitis. The significant discrepancy in ACD detection rates between personalized and standardized patch tests in women emphasizes the importance of using patient-specific products in diagnostic testing. Incorporating scalp ACD more readily into one's differential, employing individualized patch testing with trichoscopy, and accounting for neighboring symptomatic areas are all crucial elements in improving diagnostic accuracy for scalp ACD in women.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e167"},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the inclusion of women of color in lichen sclerosus treatment studies: a scoping review.","authors":"Jessica C Evans, Ekene A Ezenwa, Olushola L Akinshemoyin Vaughn","doi":"10.1097/JW9.0000000000000170","DOIUrl":"10.1097/JW9.0000000000000170","url":null,"abstract":"<p><strong>Background: </strong>Vulvar lichen sclerosus (VLS) is an underrecognized chronic inflammatory skin condition with significant clinical features and potential for malignant transformation. To date, there are no studies comparing the course of this disease in women of color to other racial groups.</p><p><strong>Objective: </strong>The objective of this study was to provide a scoping review examining racial demographic data in VLS treatment studies and specifically assessing for the inclusion of women of color.</p><p><strong>Methods: </strong>Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a primary literature search was conducted using 4 databases: Ovid Medline(R), Scopus, Cochrane, and Web of Science from all years to December 2022. We included published studies with adult women diagnosed with VLS and containing a treatment arm using topical corticosteroids. Single case reports, literature reviews, systemic reviews, meta-analyses, and reports not available in English were excluded.</p><p><strong>Results: </strong>Overall, 1340 nonduplicate studies were assessed for eligibility criteria. In total, 65 publications were included. Only 6 included racial demographic data. Black women made up at most 3.8% of the sample population and Latinx women made up at most 5.7%.</p><p><strong>Limitations: </strong>Our review focused on a specific intervention (ie, the use of topical corticosteroids for the treatment of VLS), which may restrict the generalizability of our findings to other interventions. No risk of bias assessment was done due to the scoping nature of the review.</p><p><strong>Conclusion: </strong>Women of color are underrepresented in studies of topical corticosteroid use in adult women with VLS. Intentional diversity in recruitment will enable the collection of data that is both more accurate and reflective of a broader spectrum of perspectives and life experiences.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e170"},"PeriodicalIF":0.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-induced anogenital melanosis is a very frequent finding in patients with vulvar lichen sclerosus.","authors":"Thilo Gambichler, Gülgün Erdogan, Sera S Weyer-Fahlbusch, Laura Susok","doi":"10.1097/JW9.0000000000000169","DOIUrl":"10.1097/JW9.0000000000000169","url":null,"abstract":"<p><strong>Background: </strong>Pigmented lesions such as melanosis have rarely been reported in patients with vulvar lichen sclerosus (VLS) that is typically characterized by hypopigmented lesions.</p><p><strong>Objective: </strong>We aimed to analyze systematically anogenital melanosis in a large cohort of VLS patients.</p><p><strong>Methods: </strong>We analyzed the clinical data of 198 female patients with VLS. The anogenital lesions of all patients were professionally photographed in a standardized position and illumination. Severity classification of architectural findings followed an easy-to-use clinical score. A modified Melasma Area and Severity Index and an image analysis software were used to evaluate the area and intensity of pigmentation.</p><p><strong>Results: </strong>According to the clinical score, 79 (198/39.9%) patients showed grade 1 disease, 78 (198/39.4%) grade 2, 37 (198/18.7%) grade 3, and 4 (198/2%) grade 4 disease. About 111 (56.1%) of the 198 patients had anogenital melanosis with a median modified Melasma Area and Severity Index of 3.6 (0.4-14). Univariate analysis revealed that anogenital melanosis was positively correlated with the use of topical estrogens (<i>P</i> = .0018) and negatively correlated with the use of pulsed high-dose corticosteroids plus low-dose methotrexate (PHDC-LDM, <i>P</i> = .021). On multivariable analysis, the use of topical hormone therapy turned out to be a strong independent predictor for the presence of anogenital melanosis (odds ratio: 4.57, 95% confidence interval: 1.66-12.57, <i>P</i> = .0033), whereas PHDC-LDM use was an independent predictor for the absence of anogenital melanosis (odds ratio: 0.35, 95% confidence interval: 0.15-0.84, <i>P</i> = .018).</p><p><strong>Limitations: </strong>The study includes the retrospective monocentric design.</p><p><strong>Conclusion: </strong>Anogenital melanosis is a very frequent and so far, under-reported clinical finding in VLS patients. It is likely caused by the use of topical estrogens employed for VLS treatment. In contrast, patients with more severe disease and PHDC-LDM treatment appear to develop less likely anogenital melanosis.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e169"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anogenital pruritus is associated with anxiety, depression, and other psychiatric disorders.","authors":"Alex Balfour, Christina Kraus","doi":"10.1097/JW9.0000000000000168","DOIUrl":"10.1097/JW9.0000000000000168","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e168"},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suicidal ideation in patients with vulvar lichen sclerosus.","authors":"Hannah R Chang, Madeline Ngo, Shivani Jain, Melissa M Mauskar","doi":"10.1097/JW9.0000000000000164","DOIUrl":"10.1097/JW9.0000000000000164","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e164"},"PeriodicalIF":0.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lichenoid tissue eruption of the vulva associated with immune checkpoint inhibitor.","authors":"Maya I Davis, David J DiCaudo, Leah A Swanson","doi":"10.1097/JW9.0000000000000161","DOIUrl":"10.1097/JW9.0000000000000161","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e161"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of spironolactone in treating hidradenitis suppurativa in women of childbearing age: a single-center retrospective analysis.","authors":"Suma V Gangidi, Rachel K Greene, Eric Olsen, Shanelle Jackson, Mio Nakamura","doi":"10.1097/JW9.0000000000000159","DOIUrl":"10.1097/JW9.0000000000000159","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic skin disease characterized by recurrent nodules that affect areas with a high density of apocrine sweat glands, such as the axillae and groin. Androgens are implicated in the pathophysiology of HS. Therefore, spironolactone, an antiandrogen therapy, is recommended. However, data on its use in women of childbearing age are limited, especially since its antiandrogenic effects may affect menstruation, fertility, and pubertal development.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of spironolactone in the treatment of hidradenitis suppurativa in women of childbearing age and to identify factors associated with treatment response.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on female patients aged 12 to 50 with HS treated with spironolactone at Michigan Medicine dermatology clinics from 2000 to 2021. The patients' demographic data, HS characteristics, and spironolactone responses were examined. Statistical assessments were performed to determine the efficacy indicators.</p><p><strong>Results: </strong>Of the 157 patients reviewed, 31 showed an improvement in treatment. Variables such as axillary involvement, previous treatment failures, and use of intralesional steroids were linked to a lack of improvement in spironolactone. Through adjusted multiple logistic regression analysis, a significant association was observed between improvement status and Hurley stage 3 (odds ratio = 0.15 [95% CI: 0.02-0.79], <i>P</i> = .036), suggesting that patients with Hurley stage 3 were 85% less likely to exhibit improvement in spironolactone therapy.</p><p><strong>Limitations: </strong>The study's retrospective nature and reliance on single-center data can limit generalizability. The sample size is limited and therefore affects the study's statistical power.</p><p><strong>Conclusion: </strong>Thus, spironolactone may offer therapeutic benefits for HS in women of childbearing age. However, patients with severe disease (Hurley stage 3) had reduced response rates. Further prospective studies are recommended to validate these findings and determine the most suitable patient profile for spironolactone therapy for HS.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 3","pages":"e159"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216665/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender disparities in high-quality dermatology research over the past 15 years.","authors":"Barak Zlakishvili, Amir Horev","doi":"10.1097/JW9.0000000000000160","DOIUrl":"10.1097/JW9.0000000000000160","url":null,"abstract":"<p><strong>Background: </strong>In the last 15 years, an increase in U.S. female dermatologists from 41 to 52.2% and a surge in female authorship (FAP) have been noted. Authorship is a pivotal objective measurement of academic productivity and, contribution as first or senior author, plays a major role in the promotion process of active physicians and faculty members.</p><p><strong>Objective: </strong>To validate, analyze, and clarify trends in FAP in high-quality dermatology research in the last 15 years.</p><p><strong>Methods: </strong>The Thomson Reuters Web of Science Journal Citation Reports 2021 was used to retrieve the 100 most-cited original articles from the top 5 dermatology journals (determined by 2021 impact factors) in 5 consecutive 3-year intervals between 2009 and 2023. Gender application programming interface, a gender algorithm, was used to identify FAP according to country of origin and first name. Monotonic trend test significance level was set at 5%.</p><p><strong>Results: </strong>In total, 14,187 articles were retrieved and subdivided into the 100 most-cited in 3-year intervals. A total of 418 first and 447 senior authors' gender were identified. FAP was found in 43%, 31%, and 37% of the first, last, and total authors. Trend analysis revealed a decrease in the last 15 years (<i>S</i> = -4610, <i>P</i> = .068) in senior FAP. Similarly, the trend persists in the United States (<i>S</i> = -1606, <i>P</i> = .052).</p><p><strong>Limitations: </strong>Due to the usage of a binary gender identification algorithm, Nonbinary gender could not be identified in this analysis.</p><p><strong>Conclusion: </strong>The last 15 years show an inverse relationship, with an increase in female dermatologists and a decrease in senior FAP in high-quality journals in the general dermatology community.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 2","pages":"e160"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic factors associated with hidradenitis suppurativa, a literature review.","authors":"Shannon M Eble, Oliver J Wisco, Luigi Boccuto, Brian Laffin, Veronica G Parker, Nicole J Davis, Heide S Temples","doi":"10.1097/JW9.0000000000000158","DOIUrl":"10.1097/JW9.0000000000000158","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterized by deep-seated, painful lesions most frequently occurring in intertriginous areas of the skin. HS leads to poor quality of life in affected individuals and is difficult to diagnose and treat.</p><p><strong>Objective: </strong>Understanding the genetics associated with familial inheritance may lead to a better understanding of the pathogenesis of this debilitating disease.</p><p><strong>Methods: </strong>Articles published until March 9, 2023, were identified in PubMed using the following search terms: hidradenitis suppurativa and gene* or acne inversa and gene*.</p><p><strong>Results: </strong>The rate of monogenic mutations associated with HS is less than 7%, with the most common genetic mutations reported in sporadic and familial HS cases being in <i>NCSTN</i> and less frequently in <i>PSENEN.</i> Individuals with mutations in the gamma-secretase complex tended to have more severe HS and an early age of onset.</p><p><strong>Limitations: </strong>This study was limited to the case studies available in PubMed, the majority of which used targeted gene panels to detect genetic mutations.</p><p><strong>Conclusion: </strong>Approximately 30% of individuals diagnosed with HS report having a positive family history; however, very few studies demonstrate monogenic familial transmission of HS. The case studies of syndromic HS reported a variety of genetic mutations associated with HS, some of which were familial, while others were sporadic, suggesting that other pathways may be involved in the pathogenesis of HS and other potential mutations that have yet to be evaluated. More research is needed to understand the genetic mutations in HS.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 2","pages":"e158"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11177810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of the efficacy of popular eye cream ingredients.","authors":"Hanin Hamie, Reem Yassine, Rajaa Shoukfeh, Dilara Turk, Farhan Huq, Meena Moossavi","doi":"10.1097/JW9.0000000000000156","DOIUrl":"10.1097/JW9.0000000000000156","url":null,"abstract":"<p><strong>Background: </strong>Due to the periorbital region's high susceptibility to damage from external factors, along with its tendency to demonstrate early signs of aging, periorbital skin is a common target for antiaging therapy.</p><p><strong>Objective: </strong>This review aims to evaluate the efficacy of active ingredients commonly found in eye creams, particularly focusing on their impact on periorbital skin concerns.</p><p><strong>Methods: </strong>A comprehensive review of the literature on active ingredients in eye creams, including retinoids, vitamins C and E, peptides, ceramides, hyaluronic acid, caffeine, and niacinamide, was conducted. Clinical studies assessing the efficacy of these ingredients in addressing periorbital concerns were examined.</p><p><strong>Results: </strong>Studies demonstrate the potential of these ingredients to improve various aspects of periorbital skin, including hydration, elasticity, collagen synthesis, and reduction of inflammatory mediators. Ingredients such as retinoids, vitamin C, and caffeine show promise in addressing wrinkles and hyperpigmentation, while peptides and hyaluronic acid aid in collagen production and hydration. Niacinamide and ceramides offer benefits in reducing wrinkles and enhancing the skin barrier function.</p><p><strong>Limitations: </strong>The lack of clinical trials specifically targeting eye cream formulations and periorbital skin is a notable limitation. Furthermore, the variability in study designs, sample sizes, and concentrations of active ingredients across studies complicates direct comparisons.</p><p><strong>Conclusion: </strong>The reviewed studies highlight the potential of active ingredients in eye creams to address various periorbital concerns. Further research, particularly large-scale clinical trials focusing on eye cream formulations and their efficacy on periorbital skin, is warranted to establish their significance and comparability with other dermatologic products.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"10 2","pages":"e156"},"PeriodicalIF":0.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11175953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141318962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}